Acadia Pharmaceuticals (ACAD)

• Market cap: $4.08B
• 1 day: 1%
• 5 days: 0.17%
• 1 month: -3.43%
• 3 months: 6.14%
• 6 months: 40.7%
• Year to date: 29.69%
• 1 year: 48.83%
• 5 years: -40.63%
• 10 years: -43.93%
• Sector: Healthcare
• Industry: Biotechnology

About: Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Employees: 654

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

154% more call options, than puts

Call options by funds: $19.9M | Put options by funds: $7.81M

33% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 4 (+1) [Q2]

29% more capital invested

Capital invested by funds: $2.85B [Q1] → $3.66B (+$812M) [Q2]

1.46% less ownership

Funds ownership: 102.83% [Q1] → 101.36% (-1.46%) [Q2]

4% less funds holding

Funds holding: 317 [Q1] → 305 (-12) [Q2]

15% less first-time investments, than exits

New positions opened: 46 | Existing positions closed: 54

21% less repeat investments, than reductions

Existing positions increased: 97 | Existing positions reduced: 123

Research analyst outlook

12 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $17
• Avg. target: $32
• High target: $40

12 analyst ratings

• positive: 8 67%
• neutral: 3 25%
• negative: 1 8%

TD Cowen Ritu Baral	$39	Buy Maintained	11 Sep 2025
UBS Ashwani Verma	$39	Buy Maintained	9 Sep 2025
B of A Securities Tazeen Ahmad	$27	Neutral Maintained	7 Aug 2025
Goldman Sachs Salveen Richter	$17	Sell Maintained	7 Aug 2025
RBC Capital Brian Abrahams	$40	Outperform Maintained	7 Aug 2025